28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Diuretic, ARB, and ACE-I use was, in addition to and/or independently of mean systolic blood pressure, associated with reduced risk of AD dementia in participants with normal cognition, while only diuretic use was associated with reduced risk in participants with MCI. 5 key findings →
Design: longitudinal study Participants: 1,928 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Twenty-four week supplementation with 900 mg/d DHA improved learning and memory function in ARCD and is a beneficial supplement that supports cognitive health with aging. 3 key findings →
Participants: 485 Evidence: high
Full summary, score breakdown and related studies → Original source
We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality. 5 key findings →
Participants: 165 Evidence: high
Full summary, score breakdown and related studies → Original source
Future research is warranted to examine the mechanistic basis of treatment differences, and to further assess the efficacy and safety of intranasal insulin. 4 key findings →
Participants: 12 Evidence: high
Full summary, score breakdown and related studies → Original source
Study objectives Mounting evidence implicates disturbed sleep or lack of sleep as one of the risk factors for Alzheimer's disease (AD), but the extent of the risk is uncertain. 4 key findings →
Design: systematic review Participants: 69,216 Evidence: high
Full summary, score breakdown and related studies → Original source
We randomly assigned patients with a computer-generated sequence in a 4:1 ratio overall to receive AADvac1 or placebo. 1 key finding →
Design: clinical trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
Comparable modest reductions in agitation occurred in patients receiving haloperidol, trazodone, BMT, and placebo. 4 key findings →
Participants: 149 Evidence: high
Full summary, score breakdown and related studies → Original source
Community occupational therapy intervention for patients with dementia and their care givers is successful and cost effective, especially in terms of informal care giving. 3 key findings →
Design: randomized controlled trial Participants: 135 Evidence: high
Full summary, score breakdown and related studies → Original source
Patient and caregiver factors contribute to caregiver burden in persons living with PD. 5 key findings →
Design: randomized controlled trial Participants: 175 Evidence: high
Full summary, score breakdown and related studies → Original source
Fewer than half of the older adults dispensed donepezil in Ontario would have been eligible to participate in the RCTs that established the efficacy of this drug. 4 key findings →
Design: systematic review Participants: 3,423 Evidence: high
Full summary, score breakdown and related studies → Original source
In total, 994 patients received cholinesterase inhibitor treatment (rivastigmine, n = 495; donepezil, n = 499), and 57.9% of patients completed the study. 5 key findings →
Participants: 495 Evidence: high
Full summary, score breakdown and related studies → Original source
Group 3 showed less decrease in the SIB score at 12 and 24 weeks compared with group 1 (P < 0.05). 5 key findings →
Design: clinical trial Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source
Comparing with the placebo group (n = 83, change - 1.45), the ADAS-cog12 score change in the GV-971 600-mg group (n = 76) was - 1.39 (p = 0.89) and the GV-971 900-mg group (n = 83) was - 2.58 (p = 0.30). 5 key findings →
Participants: 83 Evidence: high
Full summary, score breakdown and related studies → Original source
We investigated the effect of a multidomain lifestyle intervention on the risk of dementia estimated using the validated CAIDE risk score (post-hoc analysis). 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Individuals with cognitive profiles consistent with probable executive MCI were identified using simple assessments of global cognition, memory and executive functions in a community-dwelling older population. 2 key findings →
Design: randomized controlled trial Participants: 161 Evidence: high
Full summary, score breakdown and related studies → Original source
Both t-tau and p-tau are suitable AD blood biomarkers, and p-tau217 is more sensitive than other tau biomarkers to differentiate MCI and AD. 3 key findings →
Design: systematic review Participants: 56 Evidence: high
Full summary, score breakdown and related studies → Original source
We discovered age-dependent genetic effects, established associations between vascular-related genes (KLKB1, F12, PLIN2) and midlife plasma aβ levels, and identified a plausible Alzheimer's Disease candidate gene (ITPRIP) influencing cell death. 4 key findings →
Design: meta-analysis Participants: 725 Evidence: high
Full summary, score breakdown and related studies → Original source
There is evidence that aerobic exercise improves brain health. 3 key findings →
Design: randomized controlled trial Participants: 30 Evidence: high
Full summary, score breakdown and related studies → Original source
This meta-analysis pooled 30 studies (nearly 9,800 people from 10 countries) to see how well p-tau217 measured in blood or spinal fluid detects Alzheimer's amyloid and tau pathology compared with PET scans. 4 key findings →
Design: meta-analysis Participants: 9,787 Evidence: high
Full summary, score breakdown and related studies → Original source
This was, at the time, the largest genetic study of Alzheimer's disease ever done, comparing DNA from over 111,000 people with the disease (or a strong family history) to nearly 680,000 people without it. 4 key findings →
Design: meta-analysis Participants: 788,989 Evidence: high
Full summary, score breakdown and related studies → Original source
Among community-dwelling patients with moderate to severe dementia and their caregivers, dementia palliative care, compared with usual care, did not significantly improve patients' neuropsychiatric symptoms through 24 months. 5 key findings →
Design: RCT Participants: 201 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Then, voxel-wise brainwide association analyses were used to identify gray matter volumes (GMVs) associated with social isolation and with loneliness. 5 key findings →
Design: cohort Participants: 462,619 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer's disease (AD). 2 key findings →
Design: cohort Participants: 348 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Of a total 912 participants, there were 499 males (54.7%) and 413 females (45.3%), and the mean (SD) age was 71.1 (8.49) years. 5 key findings →
Design: cohort Participants: 912 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Mean age was 83.5 (SD, 8.5) years in cohort 1, 69.1 (SD, 10.3) years in cohort 2, and 35.8 (SD, 10.7) years in cohort 3; 38% were women in cohort 1, 51% in cohort 2, and 57% in cohort 3. 4 key findings →
Design: cross-sectional Participants: 301 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →